替尔泊肽改善2型糖尿病β细胞功能与胰岛素敏感性
替尔泊肽5、10、15mg显著改善HOMA2-B,10、15mg降低胰岛素原/胰岛素及胰岛素原/C肽比值;10mg降低HOMA2-IR,且体重减轻仅部分解释胰岛素抵抗改善,提示双受体激动具有独特降糖机制。
要点
- 替尔泊肽5、10、15mg显著提高HOMA2-B,优于安慰剂。
- 替尔泊肽10、15mg降低胰岛素原/胰岛素及胰岛素原/C肽比值,优于度拉糖肽。
- 替尔泊肽10mg降低HOMA2-IR,体重减轻仅解释13%–21%的改善。
核心结论
- 替尔泊肽改善胰岛素敏感性和β细胞功能标志物的程度大于度拉糖肽。
- 替尔泊肽的胰岛素敏感性效应仅部分归因于体重减轻,提示双受体激动具有独特降糖机制。
研究设计与样本
- 对替尔泊肽(1、5、10、15mg)、度拉糖肽(1.5mg)和安慰剂对照试验进行事后分析。
- 分析26周时空腹生物标志物,并用多元线性回归评估体重减轻对胰岛素抵抗改善的贡献。
主要发现
- 与安慰剂相比,度拉糖肽和替尔泊肽5、10、15mg显著增加HOMA2-B(P ≤ .02)。
- 与安慰剂和度拉糖肽相比,替尔泊肽10、15mg显著降低胰岛素原/胰岛素和胰岛素原/C肽比值(P ≤ .007)。
- 与安慰剂和度拉糖肽相比,替尔泊肽10、15mg显著降低空腹胰岛素(P ≤ .033),替尔泊肽10mg显著降低HOMA2-IR(P = .004)。
- 替尔泊肽1个或以上剂量显著增加脂联素、IGFBP-1和IGFBP-2(P < .05)。
- 体重减轻仅解释替尔泊肽10mg和15mg改善HOMA2-IR的13%和21%(P ≤ .028)。
临床怎么用
- 替尔泊肽可改善2型糖尿病患者的β细胞功能标志物和胰岛素敏感性,且部分效应独立于体重减轻。
- 临床评估替尔泊肽降糖效果时,除体重减轻外,还应考虑其对胰岛素敏感性的直接改善作用。
局限性
- 该分析为事后分析,可能影响因果推断。
- 研究仅评估26周时的空腹生物标志物,未涉及长期临床结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist (RA) tirzepatide demonstrated substantially greater glucose control and weight loss (WL) compared with selective GLP-1RA dulaglutide. OBJECTIVE: Explore mechanisms of glucose control by tirzepatide. DESIGN: Post hoc analyses of fasting biomarkers and multiple linear regression analysis. SETTING: Forty-seven sites in 4 countries. PATIENTS OR OTHER PARTICIPANTS: Three hundred and sixteen subjects with type 2 diabetes. INTERVENTIONS: Tirzepatide (1, 5, 10, 15 mg), dulaglutide (1.5 mg), placebo. MAIN OUTCOME MEASURES: Analyze biomarkers of beta-cell function and insulin resistance (IR) and evaluate WL contributions to IR improvements at 26 weeks. RESULTS: Homeostatic model assessment (HOMA) 2-B significantly increased with dulaglutide and tirzepatide 5, 10, and 15 mg compared with placebo (P ≤ .02). Proinsulin/insulin and proinsulin/C-peptide ratios significantly decreased with tirzepatide 10 and 15 mg compared with placebo and dulaglutide (P ≤ .007). Tirzepatide 10 and 15 mg significantly decreased fasting insulin (P ≤ .033) and tirzepatide 10 mg significantly decreased HOMA2-IR (P = .004) compared with placebo and dulaglutide. Markers of improved insulin sensitivity (IS) adiponectin, IGFBP-1, and IGFBP-2 significantly increased by 1 or more doses of tirzepatide (P < .05). To determine whether improvements in IR were directly attributable to WL, multiple linear regression analysis with potential confounding variables age, sex, metformin, triglycerides, and glycated hemoglobin A1c was conducted. WL significantly (P ≤ .028) explained only 13% and 21% of improvement in HOMA2-IR with tirzepatide 10 and 15 mg, respectively. CONCLUSIONS: Tirzepatide improved markers of IS and beta-cell function to a greater extent than dulaglutide. IS effects of tirzepatide were only partly attributable to WL, suggesting dual receptor agonism confers distinct mechanisms of glycemic control.
引用
- Thomas MK, Nikooienejad A, Bray R, et al. Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes. J Clin Endocrinol Metab. 2021. PMID: 33236115. doi:10.1210/clinem/dgaa863
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。